Patents by Inventor Ashok Bhandari

Ashok Bhandari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic monomer and dimer peptides having integrin antagonist activity
    Patent number: 10301371
    Abstract: The invention relates to C to N cyclized (C-N cyclic) monomer and dimer peptide molecules, as well as peptide dimers which are connected by linker moieties at the N terminus and the C terminus of each peptide subunit, which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 28, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede
  • Opioid agonist peptides and uses thereof
    Patent number: 10278957
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 7, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Sampath Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • OPIOID AGONIST PEPTIDES AND USES THEREOF
    Publication number: 20190076400
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Application
    Filed: September 11, 2018
    Publication date: March 14, 2019
    Inventors: Sampath Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10196424
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS
    Publication number: 20190016756
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 17, 2019
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • ANALOGUES OF HEPCIDIN MIMETICS WITH IMPROVED IN VIVO HALF LIVES
    Publication number: 20190002503
    Abstract: The present invention provides hepcidin analogues with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 3, 2019
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • NOVEL a4B7 PEPTIDE DIMER ANTAGONISTS
    Publication number: 20190002500
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: December 8, 2017
    Publication date: January 3, 2019
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheikis
  • ?4?7 thioether peptide dimer antagonists
    Patent number: 10059744
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 28, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10035824
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 31, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10023614
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 17, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
    Publication number: 20180148477
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Application
    Filed: September 7, 2017
    Publication date: May 31, 2018
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY
    Publication number: 20180105572
    Abstract: The invention relates to C to N cyclized (C-N cyclic) monomer and dimer peptide molecules, as well as peptide dimers which are connected by linker moieties at the N terminus and the C terminus of each peptide subunit, which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: October 1, 2015
    Publication date: April 19, 2018
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede
  • NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS
    Publication number: 20180099995
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Application
    Filed: June 5, 2017
    Publication date: April 12, 2018
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES
    Publication number: 20180079782
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 22, 2018
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES
    Publication number: 20180079783
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 22, 2018
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES
    Publication number: 20180022778
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.
    Type: Application
    Filed: February 24, 2017
    Publication date: January 25, 2018
    Inventors: Gregory Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS
    Publication number: 20170327541
    Abstract: The present invention provides methods of making ?4?7 peptide monmer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.
    Type: Application
    Filed: March 23, 2017
    Publication date: November 16, 2017
    Inventors: Ashok Bhandari, Suresh Kumar Manthati, Mukund M. Mehrotra, Sampath-Kumar Anandan, Dinesh V. Patel
  • ?4?7 peptide monomer and dimer antagonists
    Patent number: 9809623
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: November 7, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • a4B7 integrin thioether peptide antagonists
    Patent number: 9714270
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 9624268
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease are described.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 18, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu